ClinicalTrials.gg
CompletedNCT02100553CE/BZAUpdated Mar 25, 2015

Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women

A Phase 1 interventional study of CE/BZA and Itraconazole in Healthy, sponsored by Pfizer. Completed at 2 sites in United States. Open to female participants aged 40 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-25.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
40 Years to 64 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Obesity by Pfizer — 13 open to participants now, 19 under way, 12 of them phase 3. Obesity · Pfizer.

Enrollment
51st of 62
24 · median 127
Started
2014
the only one that year
Phase 1
30 of 64
3 open now
Registered
23rd of 64
by date

Among the 64 studies in Obesity by Pfizer, this one is the 51st largest by enrollment of the 62 interventional ones that give a count, is the only one that started in 2014, is one of 30 in phase 1, and was the 23rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

13 of the 64 studies in Obesity by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 40 Years to 64 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Obesity by Pfizer, or all of them as a file.
02

Study summary

This study will assess if itraconazole will affect the blood levels of Duavee when they are given together. This study will also assess if a subject's body size affects the blood levels of Duavee.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • Postmenopausal Women
  • Obese
  • Non-obese
  • Drug Interaction with Itraconazole
  • Pharmacokinetic
04

Who can participate

Ages eligible
40 Years to 64 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Generally healthy women, aged 40-64. Intact Uterus

Exclusion criteria

Exclusion Criteria:

  • The use of oral, vaginal, or transdermal estrogen, androgen or progestin-containing medications within 30 days before study drug administration.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Other
    Non-Obese

    BMI \<30 kg/m\^2

    Drug: CE/BZA · Drug: Itraconazole

  • Other
    Obese

    BMI \>= 30 kg/m\^2

    Drug: CE/BZA · Drug: Itraconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - inf)] for BZA, total estrone adjusted for baseline and total equilin.

    AUC (0 - inf)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).

    Time frame: up to 96 hours

  2. Maximum Observed Plasma Concentration (Cmax) for BZA, total estrone adjusted for baseline and total equilin.

    Time frame: up to 96 hours

Secondary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - inf)] for unconjugated estrone, unconjugated estrone adjusted for baseline, total estrone, and unconjugated equilin.

    AUC (0 - inf)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).

    Time frame: up to 96 hours

  2. Maximum Observed Plasma Concentration (Cmax) for unconjugated estrone, unconjugated estrone adjusted for baseline, total estrone, and unconjugated equilin.

    Time frame: up to 96 hours

  3. Apparent Oral Clearance (CL/F) for all analytes.

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: up to 96 hours

  4. Time to Reach Maximum Observed Plasma Concentration (Tmax) for all analytes.

    Time frame: up to 96 hours

  5. Apparent Volume of Distribution (Vz/F) for all analytes.

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: up to 96 hours

  6. Terminal Phase Elimination Half-Life (t1/2) for all analytes.

    Terminal Phase Elimination Half-Life is the time measured for the plasma concentration to decrease by one half.

    Time frame: up to 96 hours

07

Study locations

2 sites
  • SeaView Research, Inc. (Screening Office)
    Miami, Florida 33125, United States
  • SeaView Research, Inc.
    Miami, Florida 33126, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2014
First posted
Apr 1, 2014
Start
Apr 2014
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Last update
Mar 25, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02100553
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 1, 2014
Start date
Apr 2014
Primary completion
Jun 2014
Completion
Jun 2014
Last update
Mar 25, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itraconazole

Start the discussion